Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
regtizumab
- Development stage
- Preclinical
- Lead developer
- Shaperon
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Regtizumab is a preclinical-stage bispecific antibody being developed by Shaperon for the treatment of solid tumors. It is part of Shaperon's NanoMab platform, which utilizes camelid-derived single-domain antibodies (nanobodies) to create smaller, more stable therapeutic molecules. Regtizumab is designed to simultaneously target Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and a tumor-associated antigen (TAA). By binding to both targets, the drug aims to provide localized immune checkpoint inhibition within the tumor microenvironment, potentially enhancing the anti-tumor activity of T cells while reducing the systemic toxicity often associated with conventional CTLA-4 inhibitors.
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)MAGEA8 (Melanoma-associated antigen 8)
Beyond the preview
Go deeper on regtizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on regtizumab.